According to a study presented at the 2011 European Multidisciplinary Cancer Congress, children born to women who received chemotherapy during pregnancy do not appear to have an increased risk of heart or cognitive problems. Since relatively few women are diagnosed with cancer during pregnancy, data regarding the effects of chemotherapy during pregnancy are limited. Determining [...]
A large proportion of cancer patients do not enroll in clinical trials, and those who do participate may not adequately represent age groups, cancer stages, cancer types, and racial and ethnic groups. These findings were recently reported in the Annals of Surgery. Clinical trials are the process through which medications ultimately become approved by the [...]
Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does reduce recurrence of brain metastases. These findings were recently published in the Journal of Clinical Oncology.[1] One common [...]
The U.S. Food and Drug Administration (FDA) has expanded the approval of Herceptin® (trastuzumab) to include the initial treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction in combination with chemotherapy.[1] Herceptin is a targeted therapy that has made important contributions to improved outcomes among women with HER2-positive breast cancer. HER2 is also [...]
Afinitor® (everolimus) may be a promising treatment option for patients with metastatic gastric cancer who have undergone previous treatment, according to a study published in the Journal of Clinical Oncology. Afinitor is an oral targeted therapy that works by inhibiting a protein known as the mammalian target of rapamycin (mTOR). The mTOR protein plays an [...]
According to the results of a Phase III clinical trial, treatment with the targeted therapy Herceptin® (trastuzumab) improves survival among patients with HER2-positive, advanced and inoperable stomach cancer. These results were presented at a major European cancer conference. Herceptin is a targeted therapy that has made important contributions to improved outcomes among women with HER2-positive [...]
Regular aspirin use may reduce the risk of distal stomach cancer (cancer in the lower part of the stomach). These results were published in the American Journal of Epidemiology. Cancer of the stomach is called gastric cancer. Gastric adenocarcinoma is the most common type of stomach cancer. It arises from cells that line the surface [...]
